Examiner: LEESER, ERICH A

Tech Center 1600 • Art Units: 1622 1624

This examiner grants 82% of resolved cases

Analysis

Erich A Leeser is an examiner in Tech Center 1600 and Art Unit 1622. With 966 resolved cases, the allowance rate is 81.8 percent. The interview lift is 13.3 percent, which is a moderate boost to the chances of allowance.

The median days to allowance is 766. This is an efficient timeline for the 966 resolved cases. The 81.8 percent allowance rate suggests a high probability of success. The 13.3 percent interview lift indicates that interviews are a helpful part of the process.

Practitioners should expect a 766-day median timeline for allowance. The allowance rate is a strong indicator of a favorable prosecution environment in Art Unit 1622. The interview lift across resolved cases shows that direct communication can provide a benefit. This data set suggests a highly efficient path to success.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

81.8%

Allow Rate

+21.8% vs TC avg

984

Total Applications

+13.3%

Interview Lift

767

Avg Prosecution Days

Based on 969 resolved cases, 2023–2026

Rejection Statute Breakdown

1.5%

§101 Eligibility

23.6%

§102 Novelty

15.1%

§103 Obviousness

39.4%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
19426142	PRMT5 INHIBITORS AND METHODS OF USE	Non-Final OA	SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED
18397327	NANOPARTICLES WITH ANTI-INFLAMMATORY PROPERTIES AND ENHANCED PENETRATION ACROSS THE BIOLOGICAL BARRIERS TO DELIVER ENCAPSULATED DRUGS	Non-Final OA	The Board of Trustees of The University of Alabama
18557991	COMPOSITION FOR PROMOTING BONE FORMATION OR TREATING BONE DISEASE BY ACTING ON OSTEOBLAST MITOCHONDRIA	Non-Final OA	SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
18543130	COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND TITANIUM DIOXIDE	Non-Final OA	L'OREAL
18549158	Treatment of Breast Cancer with Amcenestrant and Palbociclib	Non-Final OA	Pfizer Inc.
18763484	INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE	Non-Final OA	JANSSEN PHARMACEUTICA NV
18579114	BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY	Final Rejection	NURIX THERAPEUTICS, INC.
18409158	OLANZAPINE COMPOSITIONS AND METHODS OF USE	Non-Final OA	MEDINCELL SA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy